Delivering Transgenic DNA Exceeding the Carrying Capacity of AAV Vectors

Abstract

Gene delivery using recombinant adeno-associated virus (rAAV) has emerged to the forefront demonstrating safe and effective phenotypic correction of diverse diseases including hemophilia B and Leber’s congenital amaurosis. In addition to rAAV’s high efficiency of transduction and the capacity for long-term transgene expression, the safety profile of rAAV remains unsoiled in humans with no deleterious vector-related consequences observed thus far. Despite these favorable attributes, rAAV vectors have a major disadvantage preventing widespread therapeutic applications; as the AAV capsid is the smallest described to date, it cannot package “large” genomes. Currently, the packaging capacity of rAAV has yet to be definitively defined but is approximately 5 kb, which has served as a limitation for large gene transfer. There are two main approaches that have been developed to overcome this limitation, split AAV vectors, and fragment AAV (fAAV) genome reassembly (Hirsch et al., Mol Ther 18(1):6–8, 2010). Split rAAV vector applications were developed based upon the finding that rAAV genomes naturally concatemerize in the cell post-transduction and are substrates for enhanced homologous recombination (HR) (Hirsch et al., Mol Ther 18(1):6–8, 2010; Duan et al., J Virol 73(1):161–169, 1999; Duan et al., J Virol 72(11):8568–8577, 1998; Duan et al., Mol Ther 4(4):383–391, 2001; Halbert et al., Nat Biotechnol 20(7):697–701, 2002). This method involves “splitting” the large transgene into two separate vectors and upon co-transduction, intracellular large gene reconstruction via vector genome concatemerization occurs via HR or nonhomologous end joining (NHEJ). Within the split rAAV approaches there currently exist three strategies: overlapping, trans-splicing, and hybrid trans-splicing (Duan et al., Mol Ther 4(4):383–391, 2001; Halbert et al., Nat Biotechnol 20(7):697–701, 2002; Ghosh et al., Mol Ther 16(1):124–130, 2008; Ghosh et al., Mol Ther 15(4):750–755, 2007). The other major strategy for AAV-mediated large gene delivery is the use of fragment AAV (fAAV) (Dong et al., Mol Ther 18(1):87–92, 2010; Hirsch et al., Mol Ther 21(12):2205–2216, 2013; Lai et al., Mol Ther 18(1):75–79, 2010; Wu et al., Mol Ther 18(1):80–86, 2010). This strategy developed following the observation that the attempted encapsidation of transgenic cassettes exceeding the packaging capacity of the AAV capsid results in the packaging of heterogeneous single-strand genome fragments (<5 kb) of both polarities (Dong et al., Mol Ther 18(1):87–92, 2010; Hirsch et al., Mol Ther 21(12):2205–2216, 2013; Lai et al., Mol Ther 18(1):75–79, 2010; Wu et al., Mol Ther 18(1):80–86, 2010). After transduction by multiple fAAV particles, the genome fragments can undergo opposite strand annealing, followed by host-mediated DNA synthesis to reconstruct the intended oversized genome within the cell. Although, there appears to be growing debate as to the most efficient method of rAAV-mediated large gene delivery, it remains possible that additional factors including the target t...

Going non-viral: theSleeping Beautytransposon system breaks on through to the clinical side

“…This is in sharp contrast to popular viral gene delivery systems, where packaging into infectious viral particles sets a strict limitation to the size of cargo to be incorporated. Indeed, recombinant vectors based on AAV are not competent to package vector genomes >5 kb (Hirsch et al, 2016;Salganik et al, 2015), and both retroviral and lentiviral vectors undergo a severe loss of titer beyond a vector size of $8-10 kb Sinn et al, 2005).…”

Gene Therapy with the Sleeping Beauty Transposon System

“…33, No. 11 853 genomes >5 kb [35,36], and both retroviral and lentiviral vectors undergo a severe loss of titer beyond a vector size of $8-10 kb [37,38]], and its superior biosafety profile [29,[39][40][41][42] (discussed below in 'Safety aspects of Sleeping Beauty transposition').…”

Methods and Applications of CRISPR-Mediated Base Editing in Eukaryotic Genomes

“…However, base editors are large fusion proteins that exceed the packaging capacity of AAV. Further efforts to reduce the size (Friedland et al, 2015; Zetsche et al, 2015b) and limit immunogenicity of base editing components or vehicles (Abudayyeh et al, 2016; Bessis et al, 2004; Chew et al, 2016; Hirsch et al, 2016; Wang et al, 2017; Yin et al, 2016; Zuris et al, 2015) may also improve their clinical utility.…”